Peptide Reference
Ipamorelin
Ipamorelin Acetate
A growth hormone releasing peptide (GHRP) that selectively stimulates the pituitary to release growth hormone without affecting cortisol or prolactin. Known as the cleanest GHRP with minimal side effects.
Status
clinical
Category
growth hormone
Typical cost
$40-80/vial (5mg)
Mechanism
Binds to ghrelin receptors in the hypothalamus and pituitary, triggering pulsatile growth hormone release. Does not significantly raise cortisol or prolactin unlike other GHRPs. Maintains natural GH pulsatility.
Potential benefits
- Increased growth hormone
- Fat loss
- Muscle preservation
- Improved sleep
- Faster recovery
- Anti-aging effects
- Better skin quality
Reported side effects
- Increased hunger
- Headache
- Water retention
- Injection site reactions
- Numbness/tingling
Common dosing references
subcutaneous
100-300mcg · 1-3x daily
8-12 weeks
Research notes
Ipamorelin growth hormone stimulation
1998
Demonstrated selective GH release without cortisol or prolactin elevation in clinical studies
Ipamorelin in growth hormone deficiency
1999
Effective at increasing IGF-1 levels with favorable safety profile
Regulatory and sourcing notes
Not FDA-approved. Available by prescription in some countries for specific indications. Research chemical status in US.
Prescription in some regions. Ensure sterile injection practices. Often combined with CJC-1295 for enhanced effects.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides